R&D | Cutting-edge science and innovative research

News

J&J plots filings after psoriasis drug clears phase 3 test

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

News

Neurogene falls again on Rett gene therapy side effects

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.

News

AbbVie bags EU nod for key drug from ImmunoGen takeover

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically cleared for folate receptor-alpha (FRα) positive, platinum-resistant

News

female scientist conducting experiment in a laboratory

Tirzepatide gets a big win in obesity-related heart failure

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the

News

Trump pick of RFK for top US health job astounds critics

Last night, news broke that President-Elect Donald Trump had nominated Robert F Kennedy Jr (aka RFK Jr) as US Health Secretary.

News

Merck grabs late-stage oncology drug from China’s Abbisko

Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT),

News

Pfizer drops twice-daily obesity therapy due to side effects

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/live.png

Webinars

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change.

News

J&J plots filings after psoriasis drug clears phase 3 test

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial.

News

Neurogene falls again on Rett gene therapy side effects

Neurogene has halted patient enrolment in the high-dose arm of its trial of Rett syndrome gene therapy, sparking another run on its shares.

Press Releases

Views & Analysis

Touring Chiesi's vision for the future at the new Biotech Ce...

Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure – black-painted and as yet under construction, gigantic cranes and all – th

News

Vir awarded $1 billion multi-year BARDA influenza contract

The US Government’s Biomedical Advanced Research and Development Authority (BARDA) has made an

Views & Analysis

R&D

The 5th Operationalize Expanded Access Programs banners

Partner Content

Returning... The 5th Operationalize Expanded Access Programs...

Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!

R&D

Growing threat of AMR: UN calls for urgent global action

In response to the rise of AMR, world leaders recently convened at the United Nations General Assembly to forge a landmark commitment, setting ambitious targets and funding initiatives to c

R&D

Sponsored

Webinar recap: Boosting recruitment and retention with SDOH ...

As the pharmaceutical industry continues its shift towards more patient-centric models, the incorporation of social determinants of health (SDOH) data has become increasingly valuable.

Deep Dive

R&D

The many trends reshaping clinical trials: An interview with...

Over the last five years, a confluence of trends have combined to reshape the reality of clinical research. COVID-19 pushed decentralised trials into the mainstream.

R&D

Heard on the pipeline hexagon graphical banner

Heard on the pipeline: AI in R&D

As has become tradition in the pharma and biotech world, 2024 kicked off with a bang as experts from around the globe gathered in San Francisco for the 42nd annual JP Morgan Health Conferen

R&D

Accelerating innovation in rare diseases

Millions of people living with rare diseases are urgently waiting for diagnosis, care, and life-changing treatment options.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

R&D

evolution of clinical research in the UK

Sponsored

The evolution of clinical research: Embracing new delivery m...

The UK is welcoming a new era of clinical trial delivery, evolving beyond the traditional site-centric approach to also embrace remote, decentralised, virtual, and hybrid trials and enablin

R&D

Sponsored

EDI in clinical research: The case for adaptive strategies a...

The topic of Equality, Diversity, and Inclusion (EDI) in health and care research participation has been gaining traction in the past few years.

Podcasts

R&D

From neurosurgery to focused ultrasound: Not if, but when

Therapeutic or focused ultrasound began being applied to neurologic conditions less than a decade ago, but its potential in a wide spectrum of brain applications is high.

R&D

LSX USA Jonah Comstock and Eloise McLennan Wrapup

Investment outlook: Key takeaways from LSX USA

Investment and strategic partnerships are the lifeblood of innovation in healthcare, driving groundbreaking discoveries and accelerating the development of life-changing therapies.

R&D

Sponsored

Tips for on-time tech transfers that stay on budget

When it comes to life sciences manufacturing, there's nothing quite so daunting as a tech transfer - moving a product from development to commercialisation, or to a new facility or CDMO, pr

Video

R&D

Jonah Comstock interview with Dr Tadaaki Taniguchi

LSX 2024 - Dr Tadaaki Taniguchi

At LSX in Boston last month, editor-in-chief Jonah Comstock caught up with Dr Tadaaki Taniguchi, chief medical officer at Astellas Pharmaceuticals to talk a bit about the company and some r

R&D

Interview with James Graham Recce Pharma

LSX 2024 - James Graham, Recce Pharma

A lot of ink has been spilled about the anti-microbial resistance space and why it’s so hard to create a profitable company in it.

R&D

Richard Young, Nicole Raleigh, Daniel Schwenk and Andrea Kloeble

Boehringer Ingelheim and Veeva: A data partnership for One M...

Boehringer’s Medicine Excellence initiative harnesses technology with the aim to build a ‘One Medicine Platform’, unifying development processes and data in a centralised platform.

White Papers

R&D

Sponsored

Rare Disease Diagnostics: Advancing Orphan Drug Development ...

This white paper is free and can be downloaded and read at your convenience

R&D

Envisioning a World Without Disease

In June, pharmaphorum came together with the Connected World Without Disease Accelerator for the inaugural World Without Disease Summit, a two-day event that brought together stakeholders f

Event

R&D

Partner Content

R&D

Partner Content

LEAP HR: Life Sciences Europe

Save the Date for LEAP HR: Life Sciences Europe! 18th-20th February, 2025, London, UK.

R&D

3rd Molecular Glue Drug Development Summit

Partner Content

Welcome to the Molecular Glue Drug Development Summit!

The Molecular Glue Drug Development Summit is back in January, 2025!

R&D

Partner Content

Welcome to the 6th RNAi-Based Therapeutics Summit!

RNAi-Based Therapeutics Returns!

J&J plots filings after psoriasis drug clears phase 3 test

Neurogene falls again on Rett gene therapy side effects

AbbVie bags EU nod for key drug from ImmunoGen takeover

Tirzepatide gets a big win in obesity-related heart failure

Trump pick of RFK for top US health job astounds critics

Merck grabs late-stage oncology drug from China’s Abbisko

Pfizer drops twice-daily obesity therapy due to side effects

Roche makes obesity play with $2.7bn deal to buy Carmot

Synthetic control arms in clinical trials: Making it happen

How synthetic control arms are changing clinical trials

J&J plots filings after psoriasis drug clears phase 3 test

Neurogene falls again on Rett gene therapy side effects

Touring Chiesi's vision for the future at the new Biotech Ce...

Vir awarded $1 billion multi-year BARDA influenza contract

Returning... The 5th Operationalize Expanded Access Programs...

Growing threat of AMR: UN calls for urgent global action

Webinar recap: Boosting recruitment and retention with SDOH ...

The many trends reshaping clinical trials: An interview with...

Heard on the pipeline: AI in R&D

Accelerating innovation in rare diseases

Beyond clinical: Boosting recruitment and retention with SDO...

The evolution of clinical research: Embracing new delivery m...

EDI in clinical research: The case for adaptive strategies a...

From neurosurgery to focused ultrasound: Not if, but when

Investment outlook: Key takeaways from LSX USA

Tips for on-time tech transfers that stay on budget

LSX 2024 - Dr Tadaaki Taniguchi

LSX 2024 - James Graham, Recce Pharma

Boehringer Ingelheim and Veeva: A data partnership for One M...

Rare Disease Diagnostics: Advancing Orphan Drug Development ...

Envisioning a World Without Disease

FT US Pharma and Biotech Summit: Live coverage

FT Live US Pharma and Biotech Summit 2023 - Day 2

FT Live US Pharma and Biotech Summit 2023

LEAP HR: Life Sciences Europe

Welcome to the Molecular Glue Drug Development Summit!

Welcome to the 6th RNAi-Based Therapeutics Summit!

J&J plots filings after psoriasis drug clears phase 3 test

Decoding physician prescribing behaviour: A data-driven jour...

Others Old
-About pharmaphorum
-Articles
--eyeforpharma Barcelona 2015
-Audio
-barelonalive 2016
-Cancer
-Diabetes
--Diabetes
-Disease Spotlight
--DMD Main
--LHON Main
-ESMO2016
-ESMO2016-related
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-Featured content right column
-Featured Event
-Jobs
--pharmaphorum-live
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
-Podcast
-Premium media
-Quintiles
--Quintiles-oncol-PC
--Quintiles - ContentIO
--Quintiles - Articles
--Quintiles - Oncol articles
-Roundtables
--AZ-roundtable-biographies-2017
--AZ-roundtable-interviews-2017
--AZ-roundtable-debate-2017
-Sales and Marketing
--News
--Insights
--Appointments
--Debates
--Debates & Insight
--Views & Analysis
--Partner Content
-Slider in events
-Slider in home page
-Slider in video
-Slider in views and analysis
-Slider in webinars
-Slider in whitepapers
-Spotlight
--Understanding HCPs
--Future of Generics
--Frontiers Health 2022
--Frontiers Health 2021
--Behavioural Science
--ASCO 2019 Live coverage
--AI in Pharma Marketing
--ASCO 2019 and the future of oncology
-Startups
--Views & Analysis
--News
-System
-Top pharmaceutical companies
--Bristol-Myers Squibb
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--Merck Inc
--GlaxoSmithKline
--Gilead
--AstraZeneca
--AbbVie
-Top pharmaceutical companies
--Merck Inc
-Top stories
-Transversal Categories
--Brexit
--Clinical
--Digital and Social Media
--US
---Articles
--UK & Europe
--Sales and Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
--Healthcare
-Veeva
-Veeva channel content articles
-Veeva channel content webinars
-Video
-Views and analysis
-Webinars in home page
-Whitepapers
Others
-Transversal Categories
--Sustainability
--Clinical
--Brexit
--Digital and Social Media
--Healthcare
--US
--UK & Europe
--Sales & Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
-Top stories
-About pharmaphorum
-Top pharmaceutical companies
--Gilead
--Merck Inc
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--GlaxoSmithKline
--Bristol-Myers Squibb
--AstraZeneca
--AbbVie
-test webinar
-System
-Startups
--News
--Views & Analysis
-Veeva channel content webinars
-Webinars in home page
--Live webinar
--Webinars On demand
-Veeva channel content articles
-Veeva
-Spotlight
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-ESMO2016-related
-ESMO2016
-Featured Event
-Disease Spotlight
--LHON Main
--DMD Main
-Diabetes
--Diabetes
-Cancer
-barelonalive 2016
-Audio
-Articles
--eyeforpharma Barcelona 2015
-Slider in whitepapers
-Featured content right column
-Jobs
--pharmaphorum-live
-Roundtables
--AZ-roundtable-interviews-2017
--AZ-roundtable-biographies-2017
--AZ-roundtable-debate-2017
-Slider in webinars
-Slider in views and analysis
-Slider in video
-Slider in home page
-Slider in events
-Quintiles
--Quintiles-oncol-PC
--Quintiles - Oncol articles
--Quintiles - ContentIO
--Quintiles - Articles
-Premium media
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
Home
-News
-Views & Analysis
-Deep Dive
-Webinars
--Live webinar
-Podcasts
-Videos
-White Papers
-Events
--JP Morgan
--LSX Investech
--Anthropy
--Reuters Pharma 2022
--World Cancer Series
--Hlth 2022
--PM Society Awards
--Patient Summit PC
--Frontiers Health 2022
--FHlive17
--ASCO 2018
-Digital Debates
-Podcasts & Videos
-Partner Content
--Events
--News
--Appointments
--Press releases
Digital
-Appointments
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Market Access
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Oncology
-Appointments
-Debates
-Insights
-News
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Patients
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
R&D
-Appointments
-Debates
-Debates & Insights
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Partner Content
-Debates & Insight
Sales & Marketing
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Spotlight on
-AI in Pharma Marketing
-ASCO 2019 and the future of oncology
-ASCO 2019 Live coverage
-Behavioural Science
-Frontiers Health 2021
-Frontiers Health 2022
-Frontiers Health 2023
-Frontiers Health 2024
-Future of Generics
-Understanding HCPs
-World Without Disease Summit
-The Future of Generics

Others Old
-About pharmaphorum
-Articles
--eyeforpharma Barcelona 2015
-Audio
-barelonalive 2016
-Cancer
-Diabetes
--Diabetes
-Disease Spotlight
--DMD Main
--LHON Main
-ESMO2016
-ESMO2016-related
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-Featured content right column
-Featured Event
-Jobs
--pharmaphorum-live
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
-Podcast
-Premium media
-Quintiles
--Quintiles-oncol-PC
--Quintiles - ContentIO
--Quintiles - Articles
--Quintiles - Oncol articles
-Roundtables
--AZ-roundtable-biographies-2017
--AZ-roundtable-interviews-2017
--AZ-roundtable-debate-2017
-Sales and Marketing
--News
--Insights
--Appointments
--Debates
--Debates & Insight
--Views & Analysis
--Partner Content
-Slider in events
-Slider in home page
-Slider in video
-Slider in views and analysis
-Slider in webinars
-Slider in whitepapers
-Spotlight
--Understanding HCPs
--Future of Generics
--Frontiers Health 2022
--Frontiers Health 2021
--Behavioural Science
--ASCO 2019 Live coverage
--AI in Pharma Marketing
--ASCO 2019 and the future of oncology
-Startups
--Views & Analysis
--News
-System
-Top pharmaceutical companies
--Bristol-Myers Squibb
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--Merck Inc
--GlaxoSmithKline
--Gilead
--AstraZeneca
--AbbVie
-Top pharmaceutical companies
--Merck Inc
-Top stories
-Transversal Categories
--Brexit
--Clinical
--Digital and Social Media
--US
---Articles
--UK & Europe
--Sales and Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
--Healthcare
-Veeva
-Veeva channel content articles
-Veeva channel content webinars
-Video
-Views and analysis
-Webinars in home page
-Whitepapers
Others
-Transversal Categories
--Sustainability
--Clinical
--Brexit
--Digital and Social Media
--Healthcare
--US
--UK & Europe
--Sales & Marketing
--Rare diseases
--R&D
--Pharma Market Access
--M&A
-Top stories
-About pharmaphorum
-Top pharmaceutical companies
--Gilead
--Merck Inc
--Teva
--Roche
--Pfizer
--Novo Nordisk
--Novartis
--GlaxoSmithKline
--Bristol-Myers Squibb
--AstraZeneca
--AbbVie
-test webinar
-System
-Startups
--News
--Views & Analysis
-Veeva channel content webinars
-Webinars in home page
--Live webinar
--Webinars On demand
-Veeva channel content articles
-Veeva
-Spotlight
-Event coverage
--ASCO-slider
--ASCO-pp
--ASCO-contributor
--ASCO 2018
-ESMO2016-related
-ESMO2016
-Featured Event
-Disease Spotlight
--LHON Main
--DMD Main
-Diabetes
--Diabetes
-Cancer
-barelonalive 2016
-Audio
-Articles
--eyeforpharma Barcelona 2015
-Slider in whitepapers
-Featured content right column
-Jobs
--pharmaphorum-live
-Roundtables
--AZ-roundtable-interviews-2017
--AZ-roundtable-biographies-2017
--AZ-roundtable-debate-2017
-Slider in webinars
-Slider in views and analysis
-Slider in video
-Slider in home page
-Slider in events
-Quintiles
--Quintiles-oncol-PC
--Quintiles - Oncol articles
--Quintiles - ContentIO
--Quintiles - Articles
-Premium media
-Medical Affairs Spotlight
--Medical Affairs Spotlight - partner
--Medical Affairs Spotlight - main
Home
-News
-Views & Analysis
-Deep Dive
-Webinars
--Live webinar
-Podcasts
-Videos
-White Papers
-Events
--JP Morgan
--LSX Investech
--Anthropy
--Reuters Pharma 2022
--World Cancer Series
--Hlth 2022
--PM Society Awards
--Patient Summit PC
--Frontiers Health 2022
--FHlive17
--ASCO 2018
-Digital Debates
-Podcasts & Videos
-Partner Content
--Events
--News
--Appointments
--Press releases
Digital
-Appointments
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Market Access
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Oncology
-Appointments
-Debates
-Insights
-News
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Patients
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
R&D
-Appointments
-Debates
-Debates & Insights
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Partner Content
-Debates & Insight
Sales & Marketing
-Debates
-Insights
-News
-Press Releases
-Views & Analysis
-Deep Dive
-Webinars
-Podcasts
-Video
-White Papers
-Event
-Debates & Insight
-Partner Content
Spotlight on
-AI in Pharma Marketing
-ASCO 2019 and the future of oncology
-ASCO 2019 Live coverage
-Behavioural Science
-Frontiers Health 2021
-Frontiers Health 2022
-Frontiers Health 2023
-Frontiers Health 2024
-Future of Generics
-Understanding HCPs
-World Without Disease Summit
-The Future of Generics

Debates & Insights

News

Press Releases

Editor's Picks

Views & Analysis

Deep Dive

Webinars

Podcasts

Video

White Papers

Event

Partner Content

Editor's Picks